B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and maintains $22 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.